News 15.10.2025 Schlieren, ZH/Alpharetta — Kuros Biosciences AG, based in Schlieren, marks the first step toward commissioning a new plant in the US with a symbolic ribbon-cutting ceremony. The official opening will follow in July 2026. According to a press release, Kuros Biosciences took the "first step" in its US expansion by cutting...
News 01.10.2025 Schlieren (Zürich), Switzerland – September 30, 2025 – Kuros Biosciences (“Kuros” or the “Company”), a leader in innovative biologic technologies, today announced the full commercial launch of the MagnetOs™ MIS Delivery System. Purpose-built for Minimally Invasive Surgical (MIS) procedures, the system is designed to meet every surgeon’s need in bone...
News 30.09.2025 SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix AG, a Swiss clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced that it has successfully completed enrollment in the Phase I clinical trial of V-212, a peptide-based, serotype-independent vaccine candidate targeting Streptococcus pneumoniae infections. “Completing enrollment in this Phase I trial marks a significant milestone for V-212,”...
News 29.09.2025 DINAMIQS, a Siegfried company (SIX: SFZN), today inaugurated its state-of-the-art cGMP manufacturing facility for viral vectors — the first of its kind in Switzerland. The new facility enables end-to-end manufacturing of viral vector gene therapies, from molecule design to aseptic drug product filling. As part of this facility, new lab...
News 29.09.2025 AL-S Pharma announced today that it has appointed Angela Genge, MD, Professor of Neurology at McGill University in Montreal, as Chief Medical Officer (CMO). With a distinguished record in amyotrophic lateral sclerosis (ALS) research and the Head of ALS Global Centre of Excellence for Research and Patient Care at McGill,...